Spondyloarthritis & psoriatic arthritis
Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases
Main finding · SpA development, CD cohort (106 new SpA diagnoses)Result — go to the resultOdds ratio 0.4 95% CI 0.2–0.8Authors' conclusion
bDMARDs treatment had an impact in reducing SpA development and clinical associated risk factors to transition from IBD to IBD-SpA emerged.
Study context
- Population
- Patients with inflammatory bowel diseases (Crohn's disease or ulcerative colitis); rheumatological assessment in those with musculoskeletal symptoms
- Participants
- 507 patients
- Exposure
- Biological disease-modifying antirheumatic drugs (bDMARDs) vs conventional DMARDs in inflammatory bowel diseases (IBD)
- bDMARDs (Crohn's disease (CD))n = 176
- cDMARDs (CD)n = 112reference
- b-tsDMARDs (ulcerative colitis (UC))n = 98
- cDMARDs (UC)n = 121reference
- Outcome
- SpA incidence (new SpA diagnosis)
Methodological detailsmultivariate analysis, Kaplan-Meier curves
- Multivariate analysis
- Kaplan-Meier curves
Main finding
As reported in the abstract
SpA development, CD cohort (106 new SpA diagnoses) · entire follow-up
Odds ratio
0.4
95% CI 0.2–0.8
adjusted p=0.01
bDMARDs (CD)vs cDMARDs (CD)
OR 0.4 (95% CI 0.2–0.8); adjusted p=0.01
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| SpA development, UC cohort (56 new SpA diagnoses) · up to 12 months of treatmentb-tsDMARDs (UC) vs cDMARDs (UC) · bDMARDs protective for SpA development | P = 0.03 |
Risk factors for spondyloarthritis (SpA), CD cohort
- Females, OR (95% CI 1.1 to 3), adjusted p=0.04
- 1.7
- Non-stricturing/non-penetrating phenotype, OR (95% CI 1.1 to 3.4), adjusted p=0.01
- 2
- Psoriasis, OR (95% CI 1 to 4.6), adjusted p=0.04
- 2.1
- Non-infectious uveitis, OR (95% CI 1.4 to 33.4), adjusted p=0.01
- 6.8
Risk factors for SpA, UC cohort
- Females, OR (95% CI 1 to 4.3), adjusted p=0.02
- 2.1
- Psoriasis, OR (95% CI 1 to 6.8), adjusted p=0.03
- 2.7
Original publication
Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases. RMD Open. Published 31 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →